Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc
Anjali Owens, MD
Molecular Precision: How Myosin Inhibitors Redefine Control
Ahmad Masri, MD, MS
Cracking the Code of Obstruction: Unmet Needs in oHCM
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
CKD-aP: Beyond the Surface
Kappa-Opioid Settings: Real-World Evidence Insights
Is CKD-aP Hiding in Your Dialysis Center?
Improving Sleep and Mental Health in Patients with CKD-aP
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Patrick Rossignol, MD, PhD
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Ellie Kelepouris, MD, FACP, FAHA
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD